Diabetes and atrial fibrillation are just some of the factors that can increase a patient's risk of being hospitalized for heart failure within one year of undergoing a successful TAVR procedure.

We spoke to executives from some of healthcare's most prominent vendors to find out what challenges are on their radar in 2022 and beyond. 

The recall is due to a malfunction risk that could, if not handled properly, cause the pump to stop working for a long period of time. This could lead to a serious injury or death, according to the recall. 

The Society of Cardiovascular Computed Tomography developed and published the new document to help educate healthcare providers who regularly treat acute chest pain in the emergency department. 

New research in JACC: Cardiovascular Interventions suggests improved collaborations between cardiologists and neurologists could help TAVR patients live longer after a periprocedural stroke. 

The heart pumps appear to provide significant benefits for patients with acute myocardial infarction- or myocarditis-related cardiogenic shock. 

Shockwave announced at TCT 2022 that it hopes to enroll up to 400 patients for a new all-female clinical trial.

According to a new analysis from MedAxiom, an American College of Cardiology company, cardiologist compensation has nearly returned to where it was before the COVID-19 pandemic. The detailed report also examined new patient visits, cardiac imaging utilization and much more.